Quarterly report pursuant to Section 13 or 15(d)

ROYALTY OBLIGATIONS NET (Details Narrative)

v3.21.1
ROYALTY OBLIGATIONS NET (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Amortization of discount on royalty obligation $ 115,334 $ 118,554
Non-cash interest expense $ 7,171,200  
Common stock shares issued, descripiton The Company issued to Joe Galligan (a holder of between 5% and 10% of the Company’s shares of common stock )  
Expected life of the arrangement 15 years  
Royalty agreements description (i) Each party would purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay each (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”).  
Lucido Agreement [Member]    
Conditions to use funds, Description The Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company’s weight loss program (“Business”) including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development